Drug treatment for multidrug-resistant Acinetobacter baumannii infections

作者：Bassetti Matteo^*; Righi Elda; Esposito Silvano; Petrosillo Nicola; Nicolini Laura

来源：Future Microbiology, 2008, 3(6): 649-660.

DOI：10.2217/17460913.3.6.649

• Acinetobacter baumannii
• antibiotic
• colistin
• imipenem
• meropenem
• resistance
• rifampin
• sulbactam
• therapy
• tigecycline

Acinetobacter boumannii has emerged in the last decades as a major cause of healthcare-associated Infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. boumannii Is a rapidly emerging pathogen in healthcare settings, where it causes infections that include bacteremia, pneumonia, meningitis, and urinary tract and wound Infections. Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to the carbapenems. Other therapeutic options include sulbactam, aminoglycosides, polymixyns and tigecycline. The discovery of new therapies coupled with the development of controlled clinical trial antibiotic testing combinations and the prevention of transmission of MDR Acinetobacter infection are essential to face this important hospital problem,

• 出版日期2008-12